Skip to content
Menu

Citizens Maintains Market Outperform on Microbot Medical, Lowers Price Target to $2

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citizens analyst Daniel Stauder maintains Microbot Medical (NASDAQ:MBOT) with a Market Outperform and lowers the price target from $2.5 to $2.

Citizens analyst Daniel Stauder maintains Microbot Medical (NASDAQ:MBOT) with a Market Outperform and lowers the price target from $2.5 to $2.

Read at benzinga.com